64 results about "Disorder diabetes mellitus" patented technology

The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols.

Biologically active peptides that are derived from or are similar to sequences of the alphaS1-, alphaS2-, beta- or kapa-casein fractions of milk casein. These peptides are capable of immune modulation and other therapeutic activities, including but not limited to stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, diabetes, hypercholesterolemia, hematological disorders and viral-related diseases.

The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, diabetes, a cellular proliferative disorder, a skin disorder, a radiation-induced injury, a wound or an inflammatory disease comprising administering an effective amount of a Purine Compound to a subject in need thereof.

The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and / or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and / or inflammation related diseases, diabetes and / or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

The present invention relates to compounds of formula 1or pharmaceutically acceptable salts thereof, whereinone of R1 and R2 is methyl, ethyl or isopropyl, and the other is H;R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H;R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups;R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2.A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

The invention provides an anti-human IL-33 monoclonal antibody and application thereof. By taking recombinant human IL-33 as an immunogen, a murine anti-human IL-33 monoclonal antibody is prepared through a hybridoma technique; binding activity analysis is carried out on the murine antibody, blocking activity analysis is carried out on binding of IL-33 and ST2, sequencing is carried out, a human-mouse chimeric anti-human IL-33 monoclonal antibody is constructed, and kinetic parameters of the chimeric antibody are detected. On the basis of performance analysis of the murine antibody and the chimeric antibody, a humanized anti-human IL-33 monoclonal antibody is constructed by adopting a CDRs transplantation technology and a complementary determining region (CDR) mutation design, kinetic parameters and affinity of the humanized antibody are detected, and IL33-induced cytokine release is blocked. The anti-human IL-33 monoclonal antibody has relatively high affinity to IL-33, can effectively block binding of IL-33 and a receptor ST2 thereof, inhibits immune response related to an IL-33 / ST2 pathway, and has a good application prospect in treatment of asthma, inflammatory diseases, diabetes and autoimmune diseases.

The invention belongs to the field of biotechnology, and relates to an experimental animal model for transforming nonalcoholic steatohepatitis into liver cancer. In particular, a large and mouse model of nonalcoholic chronic steatohepatitis (NASH) and chronic steatohepatitis developing into chronic liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can be used for chronic fatty Liver, steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes, in vivo experiments of related mechanisms of diabetic complications, new drug development, and non-alcoholic steatohepatitis (NASH), liver It has extremely high application value in the study of the pathogenesis of fibrosis and liver cancer and in drug development.

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and / or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and / or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and / or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The present invention relates to modulators of FAS and DRs and their method of use in the treatment and prevention of diseases and pathologies related to accumulation of senescent cells during aging, such as cancer, chronic obstructive pulmonary disease (COPD), osteoarthritis, atherosclerosis, neurodegenerative diseases, diabetes, and many others. The present invention also relates to pharmaceutical compositions containing these compounds as well as various uses thereof.

The invention discloses an astopic monoclonal antibody OIF-KG4 of osteoinductive factor (OIF) protein and OIF-KG4 immune globulin, segment and immune coupler and drug component, which also provides an agent box to test tumour, obesity, diabetes, hypertension and hyperlipemia.

The present invention relates to an MG53 mutant, wherein the MG53 mutant is identical to the amino acid sequence of a wild-type MG53 except for at least one serine in the coiled-coil-SPRY region of the wild-type MG53, which is deleted and / or mutated into any other non-serine or non-threonine amino acid(s). The present invention also relates to a pharmaceutical composition comprising the MG53 mutant, a nucleic acid encoding the MG53 mutant, a method for preparing the MG53 mutant, use of the MG53 mutant in the manufacture of a medicament for treating heart diseases, diabetic cerebrovascular diseases, diabetic ocular complications, diabetic neuropathy, diabetic foot, kidney diseases, and diseases associated with cellular and / or tissue damage. In particular, the MG53 mutant of the present invention may avoid or reduce metabolic side effects, such as, insulin resistance, obesity, diabetes, hypertension, dyslipidemia, etc., brought by the wild-type MG53, while treating heart diseases, diabetic cerebrovascular diseases, diabetic ocular complications, diabetic neuropathy, diabetic foot, kidney diseases, and diseases associated with cellular and / or tissue damage.

Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing.

Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.

The invention discloses a method for amplifying and activating CIK lymphocyte by using a host cell transfected with functional protein in combination with multiple kinds of protein. The method has the advantages that compared with the prior art, CIK lymphocyte amplified and activated through the method has higher purity, higher amplifying efficiency and higher capability of killing tumor and TAMs in a tumor microenvironment. The method has broad prospects in the aspect of controlling and relieving the progression of part of diseases such as cancer, infectious diseases and diabetes mellitus or the aspects of organ transplantation and hepatitis B.

The invention relates to the field of plant gene engineering and provides a sequence of a human insulin gene designed and synthesized according to plant preferred codons. A plant expression vector isbuilt for the synthetic human insulin gene, so that the gene can be transferred into tomatoes by an agrobacterium rhizogenes-mediated method under the drive of a CaMV 35S promoter and a fruit-specificpromoter 2A12 to express human insulin in tomato fruit. The tomatoes capable of making human insulin can be used as a convenient oral product for preventing and treating insulin-dependent diabetes mellitus and autoimmune disorder diabetes mellitus, and human insulin can be extracted from the tomatoes to be made into injection preparations.

The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP-IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, hypertension, and glaucoma of such other enumerated conditions as can be treated with inhibitors of DPP-IV and beta blockers.